Hydroxymethylglutaryl-CoA Reductase Inhibitors
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
	"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
    
			
			
				
				
					
						| Descriptor ID | D019161 | 
					
						| MeSH Number(s) | D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370 | 
					
						| Concept/Terms | Hydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA Reductase InhibitorsInhibitors, Hydroxymethylglutaryl-CoA ReductaseReductase Inhibitors, Hydroxymethylglutaryl-CoAInhibitors, HMG-CoA ReductaseInhibitors, HMG CoA ReductaseReductase Inhibitors, HMG-CoAHMG-CoA Reductase InhibitorsHMG CoA Reductase InhibitorsStatins, HMG-CoAHMG-CoA StatinsStatins, HMG CoAInhibitors, Hydroxymethylglutaryl-CoAHydroxymethylglutaryl-CoA InhibitorsInhibitors, Hydroxymethylglutaryl CoAStatinsInhibitors, Hydroxymethylglutaryl-Coenzyme AHydroxymethylglutaryl-Coenzyme A InhibitorsInhibitors, Hydroxymethylglutaryl Coenzyme A
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 1996 | 0 | 1 | 1 | 
| 2002 | 1 | 0 | 1 | 
| 2007 | 2 | 1 | 3 | 
| 2008 | 1 | 2 | 3 | 
| 2009 | 1 | 0 | 1 | 
| 2010 | 2 | 1 | 3 | 
| 2011 | 1 | 0 | 1 | 
| 2013 | 2 | 1 | 3 | 
| 2014 | 2 | 2 | 4 | 
| 2015 | 2 | 2 | 4 | 
| 2016 | 4 | 1 | 5 | 
| 2017 | 4 | 2 | 6 | 
| 2018 | 2 | 2 | 4 | 
| 2019 | 2 | 1 | 3 | 
| 2020 | 1 | 0 | 1 | 
| 2022 | 2 | 0 | 2 | 
| 2025 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
						
					
								- 
								Tetraspanin-enriched membrane domains regulate vascular leakage by altering membrane cholesterol accessibility to balance antagonistic GTPases. Nat Cardiovasc Res. 2025 Aug; 4(8):1011-1033. 
- 
								A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022 04; 42(4):320-333. 
- 
								Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. Diabetologia. 2022 04; 65(4):587-603. 
- 
								Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020 01 08; 22(1):5. 
- 
								Lathosterolosis: An Extremely Rare Inherited Condition Associated With Progressive Liver Disease. J Pediatr Gastroenterol Nutr. 2019 11; 69(5):e142-e145. 
- 
								Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke. Platelets. 2020; 31(2):236-241. 
- 
								Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J Pediatr Endocrinol Metab. 2019 Apr 24; 32(4):327-334. 
- 
								Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 01; 123(11):1788-1795. 
- 
								Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Rev Cardiovasc Ther. 2018 Nov; 16(11):825-835. 
- 
								Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J. 2019 01; 207:10-18.